Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2025Turkish Journal of Clinics and LaboratoryOpen Access

Bladder-sparing trimodal therapy in elderly patients with muscle-invasive bladder cancer: a real-world single-center experience

View Full Paper
Ask AI
Bookmark
Share

Authors

VAVolkan AslanHAHüseyin AtacanAUAybala Nur Ucgul

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals improved survival in elderly muscle-invasive bladder cancer patients receiving trimodal therapy, suggesting important prognostic indicators.

Key Points

  • Overall survival estimates showed a median of 22 months for elderly patients with muscle-invasive bladder cancer receiving trimodal therapy.
  • Patients treated with platinum-based chemotherapy had improved overall survival (HR: 0.041; p = 0.015), indicating potential benefits of this approach.
  • Multivariable analysis identified higher platelet-to-lymphocyte ratio and advanced nodal stage as negative predictors of overall survival.
  • The findings support considering bladder-sparing trimodal therapy as a viable treatment for selected elderly patients with early-stage muscle-invasive bladder cancer.

Cite This Study

Aslan et al. (2025) studied this question.

synapsesocial.com/papers/68dd91d5fe798ba2fc498feehttps://doi.org/10.18663/tjcl.1738115
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Trimodality Therapy for Bladder Preservation in the Elderly Population with Invasive Bladder Cancer2014 · 23 citations
  2. 2Long-Term Outcomes in Patients With Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 02332014 · 444 citations
  3. 3Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712—A Randomized Phase II Trial2018 · 144 citations